Search results for "Akkermansia muciniphila"
showing 5 items of 5 documents
The Impact of Microbiota on the Pathogenesis of Amyotrophic Lateral Sclerosis and the Possible Benefits of Polyphenols. An Overview
2021
The relationship between gut microbiota and neurodegenerative diseases is becoming clearer. Among said diseases amyotrophic lateral sclerosis (ALS) stands out due to its severity and, as with other chronic pathologies that cause neurodegeneration, gut microbiota could play a fundamental role in its pathogenesis. Therefore, polyphenols could be a therapeutic alternative due to their anti-inflammatory action and probiotic effect. Thus, the objective of our narrative review was to identify those bacteria that could have connection with the mentioned disease (ALS) and to analyze the benefits produced by administering polyphenols. Therefore, an extensive search was carried out selecting the most…
Cross-regional view of functional and taxonomic microbiota composition in obesity and post-obesity treatment shows country specific microbial contrib…
2019
This work was supported by CONICYT-Chile through the FONDECYT [n° 3160525] (DM) and by Universidad San Sebastián, and by grants to AM from the Spanish Ministry of Economy and Competitiveness (projects SAF2012-31187, SAF2013-49788-EXP, SAF2015-65878-R), Carlos III Health Institute (Projects PIE14/00045 and AC15/00022), Generalitat Valenciana (Project PrometeoII/2014/065 and Prometeo/2018/A/133), Asociación Española Contra el Cancer (Project AECC 2017-1485) and co-financed by the European Regional Development Fund (ERDF).
A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms
2023
Akkermansia muciniphila is a mucin-degrading bacterium of the intestinal niche, exerting beneficial effects on the host metabolic profile. Accumulating evidence indicated Akkermansia as a promising therapeutic probiotic against metabolic disorders such as obesity, type 2 diabetes and cardiovascular diseases. However, in specific intestinal microenvironments, its excessive enrichment may be not beneficial. Conditions like inflammatory bowel disease (IBD), Salmonella typhimurium infection or post-antibiotic reconstitution may not benefit from Akkermansia supplementation. Furthermore, using Akkermansia in patients with endocrine and gynecological disorders—such as polycystic ovary syndrome (PC…
The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid…
2021
Gut microbiota plays a key role in obesity and non-alcoholic fatty liver disease (NAFLD), so synbiotics could be a therapeutic alternative. We aim to evaluate a nutritional intervention together with the administration of the bacteria Akkermansia muciniphila and the antioxidant quercetin in an in vivo model of early obesity and NAFLD. 21-day-old rats were fed with control or high-fat diet for six weeks. Then, all animals received control diet supplemented with/without quercetin and/or A. muciniphila for three weeks. Gut microbiota, NAFLD-related parameters, circulating bile acids (BAs) and liver gene expression were analyzed. The colonization with A. muciniphila was associated with less bod…
Inulīna un auzu beta-glikānu ietekme uz probiotisko baktēriju Akkermansia muciniphila augšanu un metabolismu.
2021
Cilvēku zarnu mikroflora pārdzīvoja revolūcionāras izmaiņās sakarā ar globālo industrializāciju. Masveida uztura paradumu izmaiņas saistītas ar ātrās ēdināšanas paplašināšanos, cukurotu dzērienu popularizēšanu, plašu pesticīdu izmantošanu lauksaimniecībā, kā arī palielināta sabiedrības interese uz vienkāršiem ogļhidrātiem un piesātinātiem taukiem var veicināt zarnu mikrobiotas disbiozi, kas savukārt ir cieši saistīta ar metabolā sindroma attīstīšanos. Kombinēti dažādi cukura vielmaiņas traucējumi palielina risku saslimt ar 2. tipa cukura diabētu un sirds un asinsvadu slimībām. Ir pierādīts, ka nesen izolētās gramnegatīvās baktērijas Akkermansia muciniphila daudzums apgriezti korelē ar aptau…